DelNova, Inc. is an innovative drug development company targeting unmet medical needs, including complications arising from the use of botulinum toxin (e.g., Botox®, Dysport®, Xeomin®, Jeuveau®). Our first product under development, ReViVox™ (U.S. patent allowed), is based on a clinically validated drug and will address the impacts of unintended localized paralysis from therapeutic and aesthetic botulinum toxin [BoNT] injections. There is currently no reversal agent to safely resolve these side effects; patients can wait weeks or months for drug-induced paralysis to subside. Business Summary: DelNova is developing innovative therapeutics based on an in-depth knowledge of drug delivery. Many unmet patient needs are addressable by modifying the use of known drugs to target delivery for a more efficacious, yet safer outcome. The first product under development is based on a known drug, currently approved for use in other medical conditions and with a different route of administration. The novel formulation will be used for the reversal of undesirable side effects resulting from neurotoxin injections [eg. BOTOX (TM] in both medical and cosmetic uses. Problem: Botox™ (or other BoNT) injections may result in temporary, but undesirable side effects. Transient adverse effects are due to neurotoxin infiltrating into nearby tissue, causing unintended localized paralysis. This could be attributed to either poor injection technique and/or toxin spread. There is no reversal agent to safely mitigate unintended adverse effects; the only option is to wait until the effect of the drug paralysis subsides (weeks to months). For cosmetic procedures, side effects may include droopy eyes or brows, arched eyebrows, or misalignment . In some medical procedures adverse effects may include weakened neck muscles (for migraine ) or difficulty urinating ( for overactive bladder) . Solution: ReViVox(TM); a reversal / rescue product for muscle recovery post BoNT treatment.